

Saturday, September 6th

12:15 Complement Treatment & the kidney

Chairs:

María José Soler. Hospital Universitari Vall d'Hebron. Barcelona

Sandra Herrmann. Mayo Clinic. Rochester, USA

Ex vivo C5b-9 Deposition and complement inhibition in glomerular diseases

Conxita Jacobs. Hospital Universitari Vall d'Hebron. Barcelona

C3 and complement inhibition

Fernando Caravaca. Hospital Universitario 12 de Octubre. Madrid

Thrombotic microangiopathy and complement inhibition

Miquel Blasco. Hospital Clínic. Barcelona

13:30 Closing Remarks

Oriol Bestard. Hospital Universitari Vall d'Hebron. Barcelona

María José Soler. Hospital Universitari Vall d'Hebron. Barcelona

Sandra Herrmann. Mayo Clinic. Rochester, USA

Fernando Fervenza. Mayo Clinic. Rochester, USA

1st Mayo Clinic - Vall d'Hebron

NEPHROLOGY UPDATE

September 5-6, 2025

Organized by



Scientific Endorsement



Las opiniones expresadas por los autores no reflejan necesariamente la posición de la S.E.N.



Colaborating Entities



Technical Secretariat

MUNDICONGRES, S.L.


mundicongres@mundicongres.com

91 411 6996

91 557 2175

1st Mayo Clinic - Vall d'Hebron

NEPHROLOGY UPDATE



September 5-6, 2025

Directors:



Oriol Bestard Matamoros
Hospital Universitari Vall d'Hebron. Barcelona



María José Soler Romeo
Hospital Universitari Vall d'Hebron. Barcelona



Sandra Herrmann
Mayo Clinic. Rochester, USA



Fernando Fervenza
Mayo Clinic. Rochester, USA

Venue Auditorium. Vall d'Hebron Institut de Recerca. Barcelona

08:40 Opening

09:00 Pregnancy & CKD

Chairs:

Vesna Garovic. Mayo Clinic. Rochester, USA

Sheila Bermejo. Hospital Universitari Vall d’Hebron. Barcelona

Blood pressure goals and treatments in pregnancy

Andrea Kattah. Mayo Clinic. Rochester, USA

Footprint of preeclampsia in Kidney and Heart

Vesna Garovic. Mayo Clinic. Rochester, USA

10:00 Guidelines update in polycystic and Alport diseases

Chairs:

Laia Sans. Hospital Universitari Vall d’Hebron. Barcelona

Gema Ariceta. Hospital Universitari Vall d’Hebron. Barcelona

KDIGO 2025 autosomal dominant polycystic kidney disease guideline

Vicente Torres. Mayo Clinic. Rochester, USA

ERKNet, ERA and ESPN Alport syndrome guideline

Mónica Furlano. Fundació Puigvert. Barcelona

11:00 Coffee Break

11:20 New treatments for Chronic kidney disease

Chairs:

Fernando Fervenza. Mayo Clinic. Rochester, USA

María A. Azancot. Hospital Universitari Vall d’Hebron. Barcelona

When to start SGL T2i in patients with Glomerular disease

María José Soler. Hospital Universitari Vall d’Hebron. Barcelona

GLP1 in CKD, where are we now?

Clara García Carro. Hospital Clínico San Carlos. Madrid

Targeting aldosterone as a key to transforming cardiorenal care: present & future

Sara Núñez. Hospital Universitari Vall d’Hebron. Barcelona

12:40 CAR-T Cell therapy and AKI

Chairs:

Sheila Bermejo. Hospital Universitari Vall d’Hebron. Barcelona

Clara García Carro. Hospital Clínico San Carlos. Madrid

CAR-T & AKI experience at Mayo Clinic

Sandra Herrmann. Mayo Clinic. Rochester, USA

CAR-T & AKI experience at Vall d’Hebron

Juan León. Hospital Universitari Vall d’Hebron. Barcelona

13:30 Light lunch

14:30 Personalized Kidney transplantation

Chairs:

María Meneghini. Hospital Universitari Vall d’Hebron. Barcelona

Carrie A. Schinstock. Mayo Clinic. Rochester, USA

Update on latest STAR guidelines. Controversies and new challenges

Carrie A. Schinstock. Mayo Clinic. Rochester, USA

New desensitization targets in Highly Sensitized Patients Awaiting Kidney Transplat

Oriol Bestard. Hospital Universitari Vall d’Hebron. Barcelona

To maintain or not he immunosuppression after kidney allograph failure?

Mark Stegall. Mayo Clinic. Rochester, USA

15:40 Improving Living donor Kidney transplant outcomes (Clinical Cases)

Chairs:

Joana Sellares. Hospital Universitari Vall d’Hebron. Barcelona

Mark Stegall. Mayo Clinic. Rochester, USA

How to predict Living kidney donor transplant outcomes

Naim Issa. Mayo Clinic. Rochester, USA

Pushing the limits in Living kidney donor transplantation

Francesc Moreso. Hospital Universitari Vall d’Hebron. Barcelona

09:00 Update in glomerular diseases

Chairs:

Marina López. Hospital Universitari Vall d’Hebron. Barcelona

Ladan Zand. Mayo Clinic. Rochester, USA

Monoclonal gammopathy and the kidney

Ladan Zand. Mayo Clinic. Rochester, USA

New target antigens in Membranous Nephropathy

Sanjeev Sethi. Mayo Clinic. Rochester, USA

Targeting B-Cell in ANCA vasculitis

Ulrich Specks. Mayo Clinic. Rochester, USA

A personal approach to the treatment of IgA nephropathy

Fernando Fervenza. Mayo Clinic. Rochester, USA

10:45 Coffe Break

11:15 Lights in the shadows of Lupus Nephritis

Chairs:

Oriol Bestard. Hospital Universitari Vall d’Hebron. Barcelona

Irene Agraz. Hospital Universitari Vall d’Hebron. Barcelona

Lupus nephritis: redefining treatment goals

Fernando Fervenza. Mayo Clinic. Rochester, USA

New treatments in Lupus Nephritis?

Ali Duarte. Mayo Clinic. Rochester, USA